Related Experiment Video
Updated: Feb 1, 2026
Imaging Neurons within Thick Brain Sections Using the Golgi-Cox Method
Published on: April 18, 2017
An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders
1a Department of Neurology, School of Medicine , University of California, Davis , Sacramento , CA , USA.
Introduction:
Neuroinflammation has a critical role in brain disorders. Cyclooxygenase (COX) is one of the principal drug targets for the reduction of neuroinflammation; however, studies have yielded mixed results for COX-inhibitors in the treatment of diverse acute and chronic models of epilepsy.
Areas Covered:
The article covers the effects of COX-inhibitors in epilepsy disorders. A considerable emphasis has been placed on the antiepileptic and 'disease-modifying' properties of COX-1 and COX-2 inhibitors in various preclinical epilepsy models.
Expert Opinion:
The effect of COX-inhibitors on epilepsy is inconclusive. Studies have indicated beneficial effects in preclinical models; however, proconvulsant or no effects have also been observed. These molecules may have a bidirectional role with early neuroprotective and delayed neurotoxic effects. Further systematic preclinical studies to establish the use of COX-inhibitors in epilepsy are necessary.
Insights
Cyclooxygenase (COX) inhibitors show mixed results for epilepsy treatment. While some preclinical studies suggest benefits, others indicate adverse effects, necessitating further research into their complex role in brain disorders.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Neuroinflammation is a key factor in brain disorders.
- Cyclooxygenase (COX) enzymes are primary targets for reducing neuroinflammation.
- COX-inhibitors have yielded inconsistent results in epilepsy treatment.
Purpose of the Study:
- To review the effects of COX-inhibitors in epilepsy.
- To emphasize the antiepileptic and disease-modifying potential of COX-1 and COX-2 inhibitors.
- To analyze findings from preclinical epilepsy models.
Main Methods:
- Review of existing literature on COX-inhibitors and epilepsy.
- Analysis of preclinical epilepsy models examining COX-1 and COX-2 inhibition.
- Evaluation of reported antiepileptic and disease-modifying effects.
Main Results:
- COX-inhibitor effects on epilepsy are inconclusive.
- Preclinical studies show both beneficial and proconvulsant or no effects.
- A bidirectional role, with early neuroprotection and delayed neurotoxicity, is suggested.
Conclusions:
- Further systematic preclinical studies are required.
- The use of COX-inhibitors in epilepsy remains uncertain.
- Understanding the dual role of COX-inhibitors is crucial for future therapeutic strategies.
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:19The Mantel-Cox Log-Rank Test
02:18Intrinsically Disordered Proteins
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...